Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial.

Norah G Verbout Christina U LorentzBrandon D MarkwayMichael Wallisch Thomas C Marbury Enrico Di CeraJoseph J ShatzelAndrás GruberErik I Tucker

Published in: Communications medicine (2024)

As far as we are aware, this proof-of-concept study is the first clinical trial assessing the therapeutic potential of protein C activation. The results herein support additional investigation of AB002 to safely prevent and treat thrombosis in at-risk populations.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
clinical trial
open label
pulmonary embolism
amino acid
randomized controlled trial
binding protein
newly diagnosed
study protocol
nuclear factor
inflammatory response
phase ii
placebo controlled